AliveGen, a four-year-old biotech startup in Thousand Oaks, sold the two bone- and muscle-loss products in its pipeline to Cambridge, Mass.-based Biogen for $27.5 million. Biogen said in its quarterly earnings report July 24 that it could make additional payments of up to $535 million as the products are commercialized. ALG-801 and ALG-802 target myostatin,…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
